Search clinical trials for: ALNA®

Total 16533 results

Boehringer Ingelheim

Completed

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Prostatic Hyperplasia
Boehringer Ingelheim

Completed

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Prostatic Hyperplasia
AO GENERIUM

Completed

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Fibrosis | Cystic Fibrosis

Russian Federation
Genzyme, a Sanofi Company

Completed

Growth and Development Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe Disease

United States
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Genzyme, a Sanofi Company

Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Glycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)

United States, Netherlands, United Kingdom, Germany
Megalabs
Azidus Laboratories

Not yet recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients (ENCASE)

Anemia of Chronic Kidney Disease

Uruguay
Alexion Pharmaceuticals, Inc.
Xcenda, LLC

Active, not recruiting

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Hypophosphatasia

United States
Genzyme, a Sanofi Company

Terminated

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Pompe Disease

United States
University of Colorado, Denver
Genentech, Inc.

Completed

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

Otitis Media

United States
Sanofi
Pulse Infoframe Ltd.

Recruiting

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Niemann-Pick Diseases | Acid Sphingomyelinase Deficiency

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Sandoz

Completed

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) (SENSE)

Chronic Kidney Disease

Russian Federation, Germany, Italy, Poland, Romania, Turkey, Ukraine
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Sandoz

Completed

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa (ACCESS)

Anemia | Chronic Kidney Disease (CKD)

United States
Genzyme, a Sanofi Company

Active, not recruiting

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

Glycogen Storage Disease Type II

France
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (Mini-COMET)

Glycogen Storage Disease Type II-Pompe's Disease

United States, France, Japan, Taiwan, United Kingdom
Asan Medical Center

Completed

Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors

Quality of Life | Breast Cancer

Korea, Republic of
Shire

Completed

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Gaucher Disease, Type 1

Israel, Paraguay, Argentina, Russian Federation, Tunisia
Christopher Patterson

Completed

Researching the Effects of Sleep on STep Count dUring the Postoperative Period (REST-UP)

Postoperative Complications | Delirium | Sleep | Hip Fractures

Canada
BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Alexion

Terminated

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (Annexa-S)

Surgery

United States, Germany, Israel, France, Austria, Japan
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Sanofi

Completed

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Hemophilia A

Bulgaria
Amgen

Completed

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Kidney Disease
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France
Institut Claudius Regaud

Terminated

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

Neoplasms | Anemia

France
Shire

Completed

Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

Gaucher Disease

United States, Israel, United Kingdom, Poland, Spain
AstraZeneca

Not yet recruiting

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure (ANNEXA-RS)

Urgent Surgery

Finland, Italy, Spain, United Kingdom, Belgium, United States, Switzerland, Germany, Hungary, Japan, Mexico, Austria, Australia, Israel, Czechia, Canada, Portugal, Bulgaria, China, Brazil, Taiwan, New Zealand, Slovakia, Poland, Estonia, G... and more
Merck KGaA, Darmstadt, Germany

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (ESPART)

Infertility

Germany
Kind Pharmaceuticals LLC

Active, not recruiting

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Renal Anemia

United States
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
Chiesi Farmaceutici S.p.A.

Terminated

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome

United States, Italy, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study (Curpap)

Respiratory Distress Syndrome, Newborn

Italy, Spain, Czechia, France, Portugal
Amgen

Completed

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Anemia | Non-Myeloid Malignancies
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Sports Medicine Research and Testing Laboratory

Completed

CD71 in Dried Blood Spots in Healthy Males

Healthy Athletes

United States
Amgen

Completed

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Anemia
Amgen

Completed

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Anemia | Chronic Renal Failure
Shire

Completed

Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)

Gaucher Disease

Israel, Romania, Serbia
Amgen

Completed

Study to Evaluate Effectiveness of Aranesp®

Kidney Disease
University of Louisville
James Graham Brown Cancer Center

Withdrawn

Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia (Procrit)

Anemia

United States
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Alexion Pharmaceuticals

Completed

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | LAL-Deficiency | Cholesterol Ester Storage Disease (CESD)

France, United Kingdom, United States, Canada, Czechia
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Novo Nordisk A/S

Completed

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany (WIRK)

Congenital Bleeding Disorder | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

Germany
Hoffmann-La Roche

Completed

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

Belgium, Ireland, Italy, United Kingdom
Shire

Completed

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Gaucher Disease, Type 1

Spain, Israel, United States, India, Paraguay, United Kingdom, Russian Federation, Tunisia, Argentina
Amgen

Completed

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Neoplasms | Anemia

3

Subscribe